Published in Health Business Week, January 12th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Adeza.
Report 1: Adeza (ADZA) announced that the U.S. Food and Drug Administration (FDA) has determined that Gestiva for the prevention of preterm birth in women with a history of preterm delivery is approvable subject to the completion of an additional animal study and certain other conditions.
The approvable letter also outlined post-approval clinical requirements, which are consistent with recommendations made by the FDA advisory committee in August 2006.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.